Normalizing BP in Octogenarians Could Raise Mortality
By HospiMedica International staff writers Posted on 08 May 2019 |
Pharmacologically normalizing blood pressure (BP) is associated with an increased risk for all-cause mortality for older adults, according to a new study.
Researchers at Charité Universitätmedizin (Charité; Berlin, Germany), Jewish General Hospital (Montreal, Canada), and other institutes assembled a cohort of 1,628 patients (mean age 81 years) who were treated with antihypertensive drugs at baseline, with follow-up done up to December 2016. Of these, 636 patients exhibited normalized BP, which was defined as being lower than 140/90 mm Hg during antihypertensive treatment. They then correlated BP with the risk for all-cause mortality.
The results showed that 469 patients died during 8,853 person-years of follow-up. Normalized BP was correlated with an increased risk for all-cause mortality (60.3 per 1,000 person-years), compared with non-normalized BP (48.5 per 1,000 person-years), a hazard ratio of 1.26. Risks were increased in patients aged 80 years and older and in patients with previous cardiovascular events. Risks were not increased among patients aged 70-79 years, or for those without previous cardiovascular events. The study was published on February 25, 2019, in the European Heart Journal.
“Our results show clearly that, within these groups of patients, antihypertensive treatment should be adjusted based on the needs of the individual. Careful individualized clinical assessment of potential benefits and harms of antihypertensive treatment should guide physician decision-making,” concluded lead author Antonios Douros, MD, of Charité, and colleagues. “We should move away from the blanket approach of applying the recommendations of professional associations to all groups of patients.”
The 2014 U.S. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) guideline increased the systolic BP treatment goal from less than 140/90 mm Hg to less than 150/90 mm Hg, although committee members did not recommend it unanimously. Similarly, the guideline changed targets for adults with chronic kidney disease (CKD) and diabetes from less than 130/80 mm Hg to the less than 140/90 mm Hg, the goal recommended for the general population.
Related Links:
Charité Universitätmedizin
Jewish General Hospital
Researchers at Charité Universitätmedizin (Charité; Berlin, Germany), Jewish General Hospital (Montreal, Canada), and other institutes assembled a cohort of 1,628 patients (mean age 81 years) who were treated with antihypertensive drugs at baseline, with follow-up done up to December 2016. Of these, 636 patients exhibited normalized BP, which was defined as being lower than 140/90 mm Hg during antihypertensive treatment. They then correlated BP with the risk for all-cause mortality.
The results showed that 469 patients died during 8,853 person-years of follow-up. Normalized BP was correlated with an increased risk for all-cause mortality (60.3 per 1,000 person-years), compared with non-normalized BP (48.5 per 1,000 person-years), a hazard ratio of 1.26. Risks were increased in patients aged 80 years and older and in patients with previous cardiovascular events. Risks were not increased among patients aged 70-79 years, or for those without previous cardiovascular events. The study was published on February 25, 2019, in the European Heart Journal.
“Our results show clearly that, within these groups of patients, antihypertensive treatment should be adjusted based on the needs of the individual. Careful individualized clinical assessment of potential benefits and harms of antihypertensive treatment should guide physician decision-making,” concluded lead author Antonios Douros, MD, of Charité, and colleagues. “We should move away from the blanket approach of applying the recommendations of professional associations to all groups of patients.”
The 2014 U.S. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) guideline increased the systolic BP treatment goal from less than 140/90 mm Hg to less than 150/90 mm Hg, although committee members did not recommend it unanimously. Similarly, the guideline changed targets for adults with chronic kidney disease (CKD) and diabetes from less than 130/80 mm Hg to the less than 140/90 mm Hg, the goal recommended for the general population.
Related Links:
Charité Universitätmedizin
Jewish General Hospital
Latest Critical Care News
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events